CXCL4 Contributes to the Pathogenesis of Chronic Liver Allograft Dysfunction

Figure 6

Blockade of CXCL4 protects recipient rat livers from CLAD. For the blockade experiment, either CXCL4mab (1 mg/kg) or physiological saline (control) was delivered to recipient rats (BN-to-Lewis) through the tail vein once every week from POD 5 for 2 months. (a) Survival time was more prolonged among recipient rats in the CXCL4mab-treated group than in the physiological saline group (). (b) Liver allograft function was evaluated by serum levels of AST and TBIL detected on POD 60. The AST levels in the CXCL4mab-treated group were significantly lower ( mg/dL) than those in the physiological saline group ( mg/dL, ). A similar trend was observed for TBIL levels between the CXCL4mab-treated group ( mg/dL) and the physiological saline group ( mg/dL, ). (c, d) Liver fibrosis of CLAD graft recipient rats was detected on POD 60 by Masson stain. CXCL4mab significantly alleviates recipient rat liver fibrosis after transplantation when compared with those in the physiological saline group.

(a)

(b)

(c)

(d)